RFP
BCRX icon

Root Financial Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Root Financial Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-699
Closed -$6.65K – 710
2026
Q1 		$6.65K Sell
699
-1
-0.1% -$8 ﹤0.01% 1838
2025
Q4 		$5.46K Hold
700
– – ﹤0.01% 1737
2025
Q3 		$5.31K Buy
+700
New +$5.83K ﹤0.01% 1699

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Root Financial Partners's BCRX Position: Q2 2026 in Review

Root Financial Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 699 shares — an estimated $6.65K sold.

Root Financial Partners first reported a position in BCRX in Q3 2025 and held it in 3 quarters. The position peaked at $6.65K in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Root Financial Partners reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 699 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $6.65K.
  • Root Financial Partners first reported a position in BioCryst Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Root Financial Partners's BioCryst Pharmaceuticals position peaked at $6.65K in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.